Alizapride, a new substituted benzamide, as an antiemetic during cancer chemotherapy
- 68 Downloads
- 9 Citations
Summary
In early clinical trials alizapride showed a better antiemetic activity with fewer side effects than metoclopramide. Alizapride has now been evaluated in an open dose — ranging study in 24 patients receiving strongly emetic chemotherapy. Alizapride 4–8 mg/kg was given as a 15 min infusion 0.5 h before and 1.5, 3.5, 5.5 and 8.5 h after the chemotherapy. At the dose levels of 6 and 8 mg/kg × 5, respectively 6 out-of 9 and 4 of 4 patients experienced side effects (hypotension, dizziness, profuse sweating, general malaise and diarrhoea). At 4 mg/kg × 54 of 15 patients experienced side effects due to alizapride (dyspnoea 1, diarrhoea 2, extrapyramidal syndrome 1 patient). Overall, 9 of 24 patients were partially or completely protected from nausea and vomiting. Based on this experience alizapride has antiemetic activity and few side effects in the dose of 4 mg/kg × 5.
Key words
alizapride cancer chemotherapy substituted benzamide nausea vomiting side-effects antiemetic therapyPreview
Unable to display preview. Download preview PDF.
References
- 1.Cupissol D, Favier F, Favier C (1982) Evaluation d'un nouvel anti-émétique, l'alizapride, en cancérologie. Sem Hôp Paris 58: 1370–1373Google Scholar
- 2.Fetting JH, Grochow LB, Folstein MF (1982) The course of nausea and vomiting after high-dose cyclophosphamide. Cancer Treat Rep 66: 1487–1493Google Scholar
- 3.Gralla RJ, Itri LM, Pisko SE (1981) Antiemetic efficacy of high-dose metoclopramide: randomized trials with placebo and prochlorperazine in patients with chemotherapy-induced nausea and vomiting. N Engl J Med 305: 905–909Google Scholar
- 4.Houin G, Bree F, Tillement JP (1982) Pharmacocinétique et biodisponibilité de l'alizapride chez l'homme. Sem Hôp Paris 58: 339–344Google Scholar
- 5.Joss RA, Galeazzi RL, Brunner KW (1983) Continuous infusion of high-dose metoclopramide for the prevention of nausea and vomiting in patients receiving cancer chemotherapy. Eur J Clin Pharmacol 25: 35–39Google Scholar
- 6.Laville CI, Margarit J (1982) Etude pharmacodynamique de l'Alizapride. Sem Hôp Paris 58: 323–331Google Scholar
- 7.Perrot J, Nahas G, Laville C (1981) Substituted benzamides as antiemetics. In: Treatment of cancer chemotherapy-induced nausea and vomiting. Poster DS, Penta JS, Bruno S (eds). Masson Publishing USA Inc., New York, pp 195–207Google Scholar
- 8.Seigel LJ, Longo DL (1981) The control of chemotherapy-induced emesis. Ann Intern Med 95: 352–359Google Scholar
- 9.Strum SB, McDermed JE, Opfell RW (1982) Intravenous metoclopramide. An effective antiemetic in cancer chemotherapy. JAMA 247: 2683–2686Google Scholar
- 10.Vermorken JB, Pinedo HM (1982) Gastrointestinal toxicity of cis-diamminedichloroplatinum (II) Neth J Med 25: 270–274Google Scholar